← Back to Search

Cannabinoid

Cannabidiol (CBD) for Radiculopathy

Phase 1 & 2
Waitlist Available
Led By Stephen Ross, MD
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of radicular CNCP (i.e. lumbar, cervical, thoracic)
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 post-initiation of treatment, week 2 post-initiation of treatment
Awards & highlights

Study Summary

This trial is designed to compare the effects of oral CBD to placebo in people with chronic spinal pain who are already taking opioids. It will last for two weeks, and safety and pain outcomes will be measured.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have chronic nerve pain in your back, neck or chest.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 post-initiation of treatment, week 2 post-initiation of treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 post-initiation of treatment, week 2 post-initiation of treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in CBD Plasma Levels
Change in Opioid Analgesic Plasma Levels
Secondary outcome measures
Pain
Change in Score on Pain Catastrophizing Scale (PCS)

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Cannabidiol (CBD)Active Control1 Intervention
Group II: Placebo (PCB)Placebo Group1 Intervention

Find a Location

Who is running the clinical trial?

NYU Langone HealthLead Sponsor
1,356 Previous Clinical Trials
816,521 Total Patients Enrolled
1 Trials studying Radiculopathy
120 Patients Enrolled for Radiculopathy
National Institute on Drug Abuse (NIDA)NIH
2,445 Previous Clinical Trials
2,593,962 Total Patients Enrolled
Stephen Ross, MDPrincipal InvestigatorNYU Langone Health
5 Previous Clinical Trials
426 Total Patients Enrolled

Media Library

Cannabidiol (Cannabinoid) Clinical Trial Eligibility Overview. Trial Name: NCT04760613 — Phase 1 & 2
Radiculopathy Research Study Groups: Cannabidiol (CBD), Placebo (PCB)
Radiculopathy Clinical Trial 2023: Cannabidiol Highlights & Side Effects. Trial Name: NCT04760613 — Phase 1 & 2
Cannabidiol (Cannabinoid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04760613 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any open positions for this research project?

"From what is published on clinicaltrials.gov, it seems as if this trial is still looking for volunteers. The original posting was on February 3rd, 2022 with the most recent update occurring on August 25th, 2022."

Answered by AI

Could you please share any other notable studies that have used Cannabidiol (CBD)?

"83 studies are currently underway to investigate CBD's efficacy. 18 of those studies have reached Phase 3 clinical trials. The global spread of these 311 locations running CBD trials is led by Brazil, more specifically Ribeirao Preto in Sao Paulo."

Answered by AI
~5 spots leftby Mar 2025